Atomo Diagnostics Limited
Level 1, 3-5 George Street,
Leichhardt, NSW 2040
Australia

Authorised by John Kelly, Managing Director

Pac Partners Healthcare Conference

6 April 2022

DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited ("Atomo") based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward looking statements that are based on Atomo's beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

INTRODUCTION

Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to the global market

Headquartered in Australia with international operations, Atomo develops, manufactures and sells innovative patented devices and innovative rapid tests that address unmet user needs

Increasing market traction globally selling approved Atomo finished tests to healthcare distributors and Atomo devices to diagnostic test partners (OEM)

$$$

Atomo has experienced strong growth since FY19, with **$7m** in H1 FY22 revenues from customers, exceeding FY21 revenues of $6.7m

Cash on hand at 31/1/22 of **$15.8m**, no debt

TRANSFORMING THE RAPID TESTING EXPERIENCE

FROM Traditional 'bits in a box' LFA kits

Issues with standard rapid test kits

Low user satisfaction and regulatory challenges

Complex (multiple components, too many steps and complex workflow)

High error rates (10% by healthcare professional, 30%+ by untrained self-test users)

TO Atomo's user-friendly all-in-one solution

Advantages of Atomo devices

INNOVATIVE: One integrated device, >90% of professional users prefer *

ACCURATE: Easy to use, always the right amount of blood and reagent seamlessly delivered to the test strip

RELIABLE: Less than 1% error rates (< 3% first time untrained users) *

* Based on independent studies conducted in South Africa

UNIQUE CORE CAPABILITIES

The intersection between Medical Devices & Diagnostics

IP Intensive → Less IP Intensive
More sales focused

Atomo DNA

Point-of-Care Self Testing

- Design and engineering
- Patent generation
- Prototype and test
- Co-development
- Regulatory processes
- User centric design

Core Functionality

- Blood collection
- Saliva & swab collection
- Buffer delivery
- Interlocks
- Manufacturing machinery and processes
- IFU's
- Digital, App

Devices

- Galileo
- Pascal
- Elion
- Da Vinci
- Non-Blood devices for Swab and Saliva

Finished Products

- HIV
- COVID

- Pipeline *
  - *HCV*
  - *HIV / Syphilis*
  - *Chlamydia*
  - *Wellness*

Customer Delivery

- Atomo Direct to consumer
- Subscription models
- White label brand partnerships in eHealth channels

Atomo has commercialised rapid blood test devices with a level of integrated functionally and user simplicity unmatched in the rapid test market

The company is now actively focused on commercialising integrated devices that materially improve testing with swab and saliva samples

** Products under commercial consideration / in pipeline*

ATOMO'S INTEGRATED TEST PLATFORMS

In Market

***Galileo**: supports professional & self test applications. WHO Prequalified.*

***Pascal**: with integrated buffer, supports professional & self test applications*

510k (Lumos: FebriDx in process and anticipate imminently

***Elion Self Test**: Especially designed to be the the most user friendly self-test with the most simple blood delivery system*

Getting Ready for Market

***DaVinci Combo Self Test**:*

- *two unique assays in a single rapid test.*
- *Metered sample volumes to each test strip*
- *integrated reagent delivery*

***Customizable Apps**: to support home testing and telemedicine*

***Expansion beyond blood testing**: portfolio of patents and device development that support Swab and Saliva rapid testing*



ATOMO'S BLACKBURN SWAB DEVICE

Simplifying swab based rapid testing



Large addressable market
Supports a broad range of swab test applications

Improved diagnostic performance
All premix sample delivered*

Easy accessory to implement
Compatible with existing rapid cassettes

Simple and efficient
Integration of blister and automatic sample delivery

Improved usability and less user variability
Reduced user steps*

* Device functionality and diagnostic performance still to be verified

ATOMO'S STRATEGIC FOCUS

Core Capabilities

Innovation, Co-development & Commercialisation
(device design, usability, manufacturability, IP, regulatory, co-commercialisation)

Markets

Infectious Diseases Testing
(HIV, COVID, Others)

OEM Devices
(devices, components, licenses)

Consumer Health & Wellness
(retail and emerging telehealth)

Channels

Infectious Diseases Testing:
- Go to market channel partners
- Direct to consumer
- Co-commercialization partners

OEM Devices:
- In-house supply for Finished Tests
- Direct supply to OEM device partners
- Co-commercialisation/licensing

Consumer Health & Wellness:
- Telehealth/home health
- Online wellness channels
- Pharmacy / Retail

TELEHEALTH: ESTABLISHED IN THE MARKET

Consumer Interest

76%

now interested in telehealth versus 11% usage in 2019

Investor Focus

Venture funding doubled

for digital health 2019-2020, on track to double again 2020-2021

Provider Acceptance

64%

of providers are more comfortable with telehealth

$50B

Point-of-Care Diagnostics Market by 2025

Regulatory and Reimbursement

80 new services

In the US, approved by the Centers for Medicare & Medicaid, with increasing access to virtual care

Source: McKinsey & Co, Telehealth: A quarter-trillion-dollar post-COVID-19 reality? May 2021

CORPORATE SNAPSHOT

- Strong revenue growth, with **H1 FY22 sales of $7.0m**, 53% higher than the prior comparable period
- Quality balance sheet, with >$30m in assets including **$15.8m** in cash on hand and no debt
- Strong cash receipts, with **$7.7m** in cash inflows from customers in H1 and a further $1.8m in R&D rebate receipts
- Continued **investment in R&D** and core capital items
- Experienced board and management, major shareholder support



MAJOR SHAREHOLDERS	% (UNDILUTED)
Dalraida Holdings Pty Ltd	11.45%
Global Health Investment Fund I, LLC	11.40%
Ellerston Capital	8.68%
Walker Group Holdings Pty Ltd	6.62%

BOARD AND MANAGEMENT

John Keith	Non-Executive Chairman
John Kelly	Co-founder and Managing Director
Deborah Neff	Non-Executive Director
Dr Curt LaBelle	Non-Executive Director
Dr Paul Kasian	Non-Executive Director
Will Souter	Chief Financial Officer

HIGHLIGHTS



In the US, telehealth as a share of medical consults went from 0.2% to 13% at the peak of the COVID-19 pandemic, and has stabilised at ~6% of all consults*

A proven innovator: commercialised the world's first fully integrated rapid blood tests for at-home use

Expansion into swab testing market: development of an integrated swab test device incorporating the Atomo's proprietary reagent blister and design know-how to minimise user errors and simplify steps of use

Resurgent OEM pipeline: the utility and benefits of Atomo's solutions now clearly demonstrated, the company is seeing increased OEM interest from diagnostic companies seeking to commercialise new products beyond COVID

Significantly expanded market for home-based testing: the COVID-19 pandemic has normalized at-home testing and transformed the landscape for home-based healthcare, now supported by regulators and government

Installed operations base: reducing capex, with investment in capacity now complete and the ability to manufacture 20 million Atomo cassettes annually supported by second-gen blister manufacturing machine

Strong financial position: $15.8m cash in bank as of 31 January 2022, no debt and strong Q3 revenues anticipated

* CB Insight's – 2021 Healthcare Digital Transformation Survey